AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Health-care companies declined as concerns about AbbVie and Humana weighed. Shares of AbbVie plunged, losing more than 12% of their value after the drugmaker said participants in two mid-stage trials ...

AbbVie (ABBV) Company Description: AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and ...

The AbbVie Foundation has donated $75 million toward the construction of UChicago Medicine's $815 million freestanding cancer care pavilion in Hyde Park. When the 575,000-square-foot building ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

With rising demand and an ageing population, European healthcare systems are under strain. In the second article in our ...

Health-care companies declined as concerns about AbbVie and Humana weighed. Shares of AbbVie plunged, losing more than 12% of their value after the drugmaker said participants in two mid-stage ...